Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Bigot

Showing results (81-90 of 138) with videos related to

Pageof 14
Sort By:
The French Journal of Urology|October 18, 2025
Updated 2025 French guidelines for renal cell carcinomaPierre Bigot, Zine-Eddine Khene, Romain Boissier, et al.
Minerva Urology and Nephrology|July 13, 2026
Off-clamp and on-clamp robotic-assisted partial nephrectomy in ischemia-sensitive patients: a multicenter propensity score-matched study (RAPN OFF-CLAMP study - UroCCR 187)Léo Schurdi-Levraud, Gaëlle Margue, Arna Geshkovska, et al.
BJU International|April 15, 2025
Investigation of whether renal tumours with caval thrombi induce particular risks: a multicentre study (UroCCR-174 CAVORISK)Adrien Panis, Thibaut Waeckel, Karim Bensalah, et al.
Urologic Oncology|February 14, 2013
Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinomaGéraldine Pignot, Pierre Colin, Marc Zerbib, et al.
European Urology Open Science|May 31, 2022
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 StudyMagnus Lindskog, Anna Laurell, Anders Kjellman, et al.
Urologic Oncology|November 27, 2024
Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n°157)Gaëlle Margue, Clément Klein, Bastien Parier, et al.
Clinical Genitourinary Cancer|December 31, 2024
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE)Michael Staehler, Umberto Basso, Jean-Christophe Eymard, et al.
Urologic Oncology|September 5, 2025
Peritoneal recurrence following nephrectomy for localized renal cancer: A multicenter European real-world analysis of incidence, pattern and treatment (PEMET study-UroCCR 124)Caroline Pettenati, Jean-Christophe Bernhard, Zine-Eddine Khene, et al.
European Radiology|July 19, 2023
Minimally invasive nephron-sparing treatments for T1 renal cell cancer in patients over 75 years: a comparison of outcomes after robot-assisted partial nephrectomy and percutaneous ablationRaphaël Lehrer, Francois Cornelis, Jean-Christophe Bernhard, et al.
European Urology Oncology|July 19, 2022
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell CarcinomaGéraldine Pignot, Antoine Thiery-Vuillemin, Laurence Albigès, et al.
Pageof 14

Showing results (81-90 of 138) with videos related to

Sort By:
Pageof 14
The French Journal of Urology|October 18, 2025
Updated 2025 French guidelines for renal cell carcinomaPierre Bigot, Zine-Eddine Khene, Romain Boissier, et al.
Minerva Urology and Nephrology|July 13, 2026
Off-clamp and on-clamp robotic-assisted partial nephrectomy in ischemia-sensitive patients: a multicenter propensity score-matched study (RAPN OFF-CLAMP study - UroCCR 187)Léo Schurdi-Levraud, Gaëlle Margue, Arna Geshkovska, et al.
BJU International|April 15, 2025
Investigation of whether renal tumours with caval thrombi induce particular risks: a multicentre study (UroCCR-174 CAVORISK)Adrien Panis, Thibaut Waeckel, Karim Bensalah, et al.
Urologic Oncology|February 14, 2013
Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinomaGéraldine Pignot, Pierre Colin, Marc Zerbib, et al.
European Urology Open Science|May 31, 2022
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 StudyMagnus Lindskog, Anna Laurell, Anders Kjellman, et al.
Urologic Oncology|November 27, 2024
Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n°157)Gaëlle Margue, Clément Klein, Bastien Parier, et al.
Clinical Genitourinary Cancer|December 31, 2024
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE)Michael Staehler, Umberto Basso, Jean-Christophe Eymard, et al.
Urologic Oncology|September 5, 2025
Peritoneal recurrence following nephrectomy for localized renal cancer: A multicenter European real-world analysis of incidence, pattern and treatment (PEMET study-UroCCR 124)Caroline Pettenati, Jean-Christophe Bernhard, Zine-Eddine Khene, et al.
European Radiology|July 19, 2023
Minimally invasive nephron-sparing treatments for T1 renal cell cancer in patients over 75 years: a comparison of outcomes after robot-assisted partial nephrectomy and percutaneous ablationRaphaël Lehrer, Francois Cornelis, Jean-Christophe Bernhard, et al.
European Urology Oncology|July 19, 2022
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell CarcinomaGéraldine Pignot, Antoine Thiery-Vuillemin, Laurence Albigès, et al.
Pageof 14